Resource Type

Journal Article 15

Year

2023 1

2022 2

2021 1

2020 3

2019 1

2018 2

2014 1

2013 1

2009 1

2007 1

open ︾

Keywords

lymphoma 3

immunotherapy 2

long-term follow-up 2

mantle cell lymphoma 2

TMSB4X 1

B cells 1

B-cell lymphoma 1

CAR-T cell therapy 1

COVID-19 pandemic 1

Hodgkin lymphoma 1

Id proteins 1

KIAA0372 1

Microarray 1

T cells 1

anti-CD19 chimeric antigen receptor T 1

anti-CD19 chimeric antigen receptor T cell 1

anti-CD19 chimeric antigen receptor T cells 1

bendamustine 1

bioinformatic analysis 1

bone marrow 1

open ︾

Search scope:

排序: Display mode:

study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma

Frontiers of Medicine 2022, Volume 16, Issue 2,   Pages 285-294 doi: 10.1007/s11684-021-0843-8

Abstract: bearing 4-1BB costimulatory molecule, for the treatment of patients with refractory diffuse large B-cell lymphoma

Keywords: CAR-T cell therapy     refractory diffuse large B-cell lymphoma     cytokine release syndrome     dose-limiting    

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 699-713 doi: 10.1007/s11684-022-0972-8

Abstract: strong>–50% long-term complete response in relapsed or refractory diffuse large B-cell lymphomamicroenvironments and reprogramming immune cell metabolism as effective therapeutic strategies to prevent lymphoma

Keywords: anti-CD19 chimeric antigen receptor T     immunotherapy     diffuse large B cell lymphoma     tumor microenvironment    

Analysis of the genomic landscape of primary central nervous system lymphoma using whole-genome sequencing

Frontiers of Medicine   Pages 889-906 doi: 10.1007/s11684-023-0994-x

Abstract: Primary central nervous system lymphoma (PCNSL) is an uncommon non-Hodgkin’s lymphoma with poor prognosis

Keywords: primary central nervous system lymphoma     whole-genome sequencing     TMSB4X     copy number variation    

Primary spinal epidural non-Hodgkin’s lymphoma presented with spinal cord compression syndrome

Chunquan CAI MD, PhD, Qingjiang ZHANG BM, Changhong SHEN MD, PhD,

Frontiers of Medicine 2009, Volume 3, Issue 4,   Pages 499-502 doi: 10.1007/s11684-009-0075-9

Abstract: boy suffered spinal cord compression syndrome caused by primary spinal epidural non-Hodgkin’s lymphomaHistological examination revealed a non-Hodgkin’s B-cell lymphoma.Bone marrow aspiration was negative for lymphoma involvement.

Keywords: non-Hodgkin’     s lymphoma     primary     spinal cord compression syndrome     epidural space    

extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 786-791 doi: 10.1007/s11684-020-0751-3

Abstract: anti-CD19 chimeric antigen receptor T (CAR-T) cell immunotherapy for relapsed or refractory non-Hodgkin lymphomaIn a cohort of 32 treated patients, 12 (37.5%) and 8 (25%) patients exhibited soft tissue lymphoma and

Keywords: anti-CD19 chimeric antigen receptor T cell     soft tissue     bone marrow     relapsed or refractory non-Hodgkin lymphoma    

Expression and bioinformatic analysis of lymphoma-associated novel gene KIAA0372

BAI Xiangyang, TANG Duozhuang, ZHU Tao, SUN Lishi, YAN Lingling, LU Yunping, ZHOU Jianfeng, MA Ding

Frontiers of Medicine 2007, Volume 1, Issue 1,   Pages 93-98 doi: 10.1007/s11684-007-0018-2

Abstract: The purpose of this study was to explore the differentially expressed genes in lymph-node cells (LNC) of lymphomas and reactive lymph node hyperplasia, and to perform an initial bioinformatic analysis on a novel gene, KIAA0372, which is highly expressed in the LNC of lymphomas. mRNA extracted from LNC of lymphomas and reactive lymph node hyperplasia were respectively marked with biotin and hybridized with Gene Expression Chips, resulting in differentially expressed genes. Initial bioinformatic analysis was then performed on a novel gene named KIAA0372, whose function has not yet been explored. Its structure and genomic location, its product s physical and chemical properties, subcellular localization and functional domains, were also predicted. Further, a systematic evolution analysis was performed on similar proteins from among several species. Using Gene Expression Chips, many differentially expressed genes were uncovered. Efficient bioinformatic analysis has fundamentally determined that KIAA0372 is an extracellular protein which may be involved in TGF-β signaling. Microarray is an efficient and high throughput strategy for detection of differentially expressed genes. And KIAA0372 is thought to be a potential target for tumor research using bioinformatic analysis.

Keywords: bioinformatic analysis     functional     KIAA0372     detection     Microarray    

thyroid-stimulating hormone during radiotherapy to prevent primary hypothyroidism in medulloblastoma/PNET and Hodgkin lymphoma

Maura Massimino, Marta Podda, Lorenza Gandola, Emanuele Pignoli, Ettore Seregni, Carlo Morosi, Filippo Spreafico, Andrea Ferrari, Emilia Pecori, Monica Terenziani

Frontiers of Medicine 2021, Volume 15, Issue 1,   Pages 101-107 doi: 10.1007/s11684-020-0752-2

Abstract: protective effect of suppressing TSH with L-thyroxine during RT for medulloblastoma/PNET and Hodgkin lymphoma

Keywords: iatrogenic primary hypothyroidism     late effects of radiotherapy     long-term follow-up     medulloblastoma     Hodgkin lymphoma    

Therapeutic effects of thalidomide in hematologic disorders: a review

Miao Xu, Yu Hou, Lei Sheng, Jun Peng

Frontiers of Medicine 2013, Volume 7, Issue 3,   Pages 290-300 doi: 10.1007/s11684-013-0277-z

Abstract: therapeutic effects in hematology, including those on multiple myeloma, Waldenstroem macroglobulinemia, lymphoma, mantle-cell lymphoma, myelodysplastic syndrome, hereditary hemorrhagic telangiectasia, and graft-versus-host

Keywords: thalidomide     multiple myeloma     lymphoma    

Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock

Muhammad Furqan,Yamei Chen,Akintunde Akinleye,Judy Sarungbam,Alan Gass,Karen Seiter,Delong Liu

Frontiers of Medicine 2014, Volume 8, Issue 2,   Pages 254-258 doi: 10.1007/s11684-014-0319-1

Abstract:

Mantle cell lymphoma is an aggressive subtype of B cell non-Hodgkin lymphoma.report of myocardial infiltration by this disease since the appraisal of the term “mantle cell lymphoma

Keywords: mantle cell lymphoma     bendamustine     cardiogenic shock    

Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)

Frontiers of Medicine 2022, Volume 16, Issue 5,   Pages 815-826 doi: 10.1007/s11684-021-0891-0

Abstract: Oral drugs such as ibrutinib play an important role in the treatment of mature B-cell lymphoma (BCL)

Keywords: B-cell lymphoma     oral drug     targeted therapy     immunotherapy     COVID-19 pandemic    

A rare case of B-lymphoproliferative disorder with villous lymphocytes harboring t(8;14)(q24;q32) translocation

Xiaofeng Shi, Rong Ba, Haiyan You, Qian Jiang, Jiansong Huang, Jianhua Mao, Lanxiu Han, Shuo Zhang, Qin Zhuang, Xianqiu Yu, Lixia Wang, Yun Wang, Dongya Li, Wei Zhu, Yong Zhang, Yan Zhu, Xiaodong Xi

Frontiers of Medicine 2018, Volume 12, Issue 3,   Pages 324-329 doi: 10.1007/s11684-017-0558-z

Abstract:

Splenic lymphoma with villous lymphocytes (SLVL) or splenic marginal zone lymphoma with circulating

Keywords: splenic lymphoma with villous lymphocytes     splenic marginal zone lymphoma     transformation     chromosome translocation    

Paradoxical role of Id proteins in regulating tumorigenic potential of lymphoid cells

Sumedha Roy, Yuan Zhuang

Frontiers of Medicine 2018, Volume 12, Issue 4,   Pages 374-386 doi: 10.1007/s11684-018-0652-x

Abstract: certain Id proteins are reported to act as tumor suppressors in the development of Burkitt’s lymphoma

Keywords: Id proteins     lymphoma     leukemia     T cells     B cells     tumor suppressor     oncogene    

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 711-725 doi: 10.1007/s11684-020-0808-3

Abstract: monoclonal antibodies) and the conventional chemotherapy increases the long-term survival of patients with lymphomaHowever, for patients with relapsed or treatment-resistant lymphoma, a novel treatment approach is urgentlyBased on recent clinical data, approximately 50% of patients with relapsed or refractory B-cell lymphomaCAR-T, the novel target antigens, such as CD20, CD22, CD30, and CD37, which were greatly expressed on lymphomacells, were studied under preclinical and clinical evaluations for use in the treatment of lymphoma.

Keywords: chimeric antigen receptor T (CAR-T) cell     lymphoma     cytokine release syndrome (CRS)     immune effector cell-associated    

antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 811-815 doi: 10.1007/s11684-020-0740-6

Abstract: Mantle cell lymphoma (MCL) is a distinct histological type of B-cell lymphoma with a poor prognosis.Several agents, such as proteasome inhibitors, immunomodulatory drugs, and inhibitors of B cell lymphomaantigen receptor (CAR) T-cell therapy has emerged as a novel treatment modality for r/r non-Hodgkin’s lymphoma

Keywords: anti-CD19 chimeric antigen receptor T cells     mantle cell lymphoma     relapsed or refractory     long-term follow-up    

of multiple abnormal immunologic markers is an independent prognostic factor of diffuse large B-cell lymphoma

Yiwen Cao, Zhenhua Liu, Wen Wu, Ying Qian, Qin Shi, Rong Shen, Binshen Ouyang, Pengpeng Xu, Shu Cheng, Jin Ye, Yiming Lu, Chaofu Wang, Chengde Yang, Li Wang, Weili Zhao

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 94-103 doi: 10.1007/s11684-019-0680-1

Abstract:

Autoimmune diseases (ADs) increase the risk of non-Hodgkin’s lymphoma and contribute to poor prognosisprognostic value of pretreatment immunologic markers in newly diagnosed patients with diffuse large B-cell lymphomaIn conclusion, the immunologic status was closely related to lymphoma progression, and this study provides

Keywords: immunologic marker     diffuse large B-cell lymphoma     prognosis    

Title Author Date Type Operation

study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma

Journal Article

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma

Journal Article

Analysis of the genomic landscape of primary central nervous system lymphoma using whole-genome sequencing

Journal Article

Primary spinal epidural non-Hodgkin’s lymphoma presented with spinal cord compression syndrome

Chunquan CAI MD, PhD, Qingjiang ZHANG BM, Changhong SHEN MD, PhD,

Journal Article

extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Journal Article

Expression and bioinformatic analysis of lymphoma-associated novel gene KIAA0372

BAI Xiangyang, TANG Duozhuang, ZHU Tao, SUN Lishi, YAN Lingling, LU Yunping, ZHOU Jianfeng, MA Ding

Journal Article

thyroid-stimulating hormone during radiotherapy to prevent primary hypothyroidism in medulloblastoma/PNET and Hodgkin lymphoma

Maura Massimino, Marta Podda, Lorenza Gandola, Emanuele Pignoli, Ettore Seregni, Carlo Morosi, Filippo Spreafico, Andrea Ferrari, Emilia Pecori, Monica Terenziani

Journal Article

Therapeutic effects of thalidomide in hematologic disorders: a review

Miao Xu, Yu Hou, Lei Sheng, Jun Peng

Journal Article

Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock

Muhammad Furqan,Yamei Chen,Akintunde Akinleye,Judy Sarungbam,Alan Gass,Karen Seiter,Delong Liu

Journal Article

Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)

Journal Article

A rare case of B-lymphoproliferative disorder with villous lymphocytes harboring t(8;14)(q24;q32) translocation

Xiaofeng Shi, Rong Ba, Haiyan You, Qian Jiang, Jiansong Huang, Jianhua Mao, Lanxiu Han, Shuo Zhang, Qin Zhuang, Xianqiu Yu, Lixia Wang, Yun Wang, Dongya Li, Wei Zhu, Yong Zhang, Yan Zhu, Xiaodong Xi

Journal Article

Paradoxical role of Id proteins in regulating tumorigenic potential of lymphoid cells

Sumedha Roy, Yuan Zhuang

Journal Article

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Journal Article

antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Journal Article

of multiple abnormal immunologic markers is an independent prognostic factor of diffuse large B-cell lymphoma

Yiwen Cao, Zhenhua Liu, Wen Wu, Ying Qian, Qin Shi, Rong Shen, Binshen Ouyang, Pengpeng Xu, Shu Cheng, Jin Ye, Yiming Lu, Chaofu Wang, Chengde Yang, Li Wang, Weili Zhao

Journal Article